TRACKING THE CONDITIONS FOR US IN ABOUT TWO MINUTES. WELL, NEW HERE AT FOUR. A CUTTING EDGE TEST FOR PARKINSON’S DISEASE. OUR CO-ANCHOR, TOM MCDERMOTT IS BACK NOW TO EXPLAIN HOW IT WORKS AND INTRODUCE ...

As Part of an Exploratory Outcome, ABLi Therapeutics Used CND's Syn-One Biomarker Services to Quantify and Visualize a Decrease in Phosphorylated Alpha-Synuclein in Cutaneous Nerves of Patients in a ...

The study demonstrated that the Syn-One Test detected phosphorylated alpha-synuclein in 95% of patients with a clinical diagnosis of synucleinopathy, achieving a 92.7% positivity rate for patients ...

Jon Schorr of Bainbridge Island, Washington, has hit the gym three times a week for 45 years. After a Parkinson’s diagnosis, the workouts hit different. “My brother had Parkinson’s quite badly. And ...

Despite the many signs and symptoms of Parkinson’s, it’s not always easy to diagnose, especially early in the disease. To tell if someone has Parkinson’s disease, a doctor typically performs a ...

In addition to offering its Syn-One Biomarker Services for use in biopharmaceutical sponsors' clinical trials, CND is continuing to study the use of the Syn-One Research Test and NerValence to ...

Grant funding will support the new Syn-Q Clinical Study to further investigate the quantification of P-SYN in skin biopsies using CND's Syn-One Test ® SCOTTSDALE, Ariz., Nov. 20, 2024 /PRNewswire/ -- ...